Phase 2, Open-Label, Single Arm Study, With BST-236 in Adults With R/R AML or Higher-Risk MDS
Status:
Not yet recruiting
Trial end date:
2024-03-14
Target enrollment:
Participant gender:
Summary
An open label multi center study to assess the safety and efficacy of BST-236 as single agent
in adult patients unfit for standard therapy with Acute Myeloid Leukemia (AML) or higher-risk
(HR) Myelodysplastic Syndromes (MDS) who fail to respond or relapsed following first line
therapy.
Approximately 20 adult patients with relapsed and/or refractory AML and approximately 20
adult patients with relapsed and/or refractory HR MDS, will be enrolled into the study.
Patients will be treated with 1-2 induction courses and 2-4 maintenance courses. All patients
will be followed for 1 year in the study and additional 1 year post study follow-up.